Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Multidisciplinær håndtering af svær jernforgiftning som følge af suicidalforsøg

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Erythropoietin as possible treatment of brain diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Oxygen under tryk som behandling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Comparison between temporal and rectal temperature measurement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Definition, pathology and pathogenesis of osteoarthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Hashimoto's thyroiditis as a risk factor for thyroid cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Disease Control and Gender Predict the Socioeconomic Effects of Acromegaly: A Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Ecological momentary assessments (EMAs) did not improve responsiveness of patient-reported outcomes on quality of life

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Is the alpha-galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

We tested the effect of co-treatment of acromegaly with a somatostatin analogue (SA) and a growth hormone receptor antagonist (GHA). Eleven patients underwent: 1) conventional treatment with SA, 2) discontinued treatment, 3) 6 weeks treatment with GHA (10 mg), 4) 6 weeks treatment with GHA (15 mg), 5) 3 months combined SA and GHA. Circulating IGF-I was lowered by GHA and more so with combined treatment. Treatment with GHA increased endogenous GH levels, which was partly reversed by combined treatment. Plasma glucose levels were highest during SA treatment and lowest with GHA. Co-treatment of acromegaly with SA and GHA is a promising concept.

Bidragets oversatte titelMedical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind169
Udgave nummer10
Sider (fra-til)911-3
Antal sider3
ISSN0041-5782
StatusUdgivet - 5 mar. 2007

ID: 59038968